Investigating a new protein's role in cell movement and activation processes
Official title: IPMK is a novel PI3k essential for mTORC2 activation and cell migration
Funded at University of Nevada Las Vegas · NIH-10937926 · Data updated 2026-11-12
This study is looking at a protein called IPMK to see how it helps activate another protein, AKT, which is important for how cells move around, and it aims to learn more about the processes that control this movement, which could be helpful for understanding conditions related to cell migration.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nevada Las Vegas NIH-funded |
| Lab location | 1 site (Las Vegas, United States) |
| Project start | July 18, 2024 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $187,219 |
| NIH project number | 1R16GM154726-01 |
| Project ID | NIH-10937926 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would include individuals with conditions related to abnormal cell migration, such as certain types of cancer.
✕Less likely to help
Patients with conditions unrelated to cell migration or those not affected by the pathways involving IPMK and mTORC2 may not benefit from this research.
What this research studies
This research focuses on a protein called IPMK, which is essential for activating another protein known as AKT, crucial for cell migration. The study aims to understand how IPMK influences the activation of mTORC2, a key regulator in this process, and how it affects the organization of the actin cytoskeleton, which is vital for cell movement. By exploring the molecular mechanisms and specific phosphorylation sites that impact IPMK's activity, the research seeks to uncover new insights into cell migration and its regulation.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for conditions where cell migration plays a critical role, such as cancer metastasis.
How similar studies have gone: While the specific role of IPMK in mTORC2 activation is novel, similar research has shown that targeting PI3K pathways can lead to significant advancements in cancer treatment.
Where this research is happening
-
University of Nevada Las Vegas
Las Vegas, United States Active
Researchers
- Principal investigator: Guha, Prasun — University of Nevada Las Vegas
- Study coordinator: Guha, Prasun
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.